Grifols coronavirus emergency

Grifols inmunoglobulin

Grifols reaches agreement in the US to seek anti-Covid19 therapy

After announcing that the United States considered it “basic infrastructure” in the coronavirus health emergency, Grifols has signed a multilateral collaboration agreement in that country with the U.S. Advanced Biomedical Research and Development Authority (BARDA), the U.S. Food and Drug Administration (FDA) and other federal public health agencies. The objective will be to collect plasma from patients who have recovered from Covid-19, process it and produce hyperimmune immunoglobulins.